Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | AK127 + Cadonilimab |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AK127 | AK-127|AK 127 | TIGIT Antibody 19 | AK127 is a monoclonal antibody that targets and binds to the T-cell immunoreceptor with Ig and ITIM domains (TIGIT), thereby inhibiting binding with ligands CD112 and CD155, and potentially resulting in an enhanced immune response against tumor cells (NCI Drug Dictionary). | |
Cadonilimab | AK-104|AK 104|AK104 | CTLA4 Antibody 31 Immune Checkpoint Inhibitor 148 PD-L1/PD-1 antibody 119 | Cadonilimab is a bispecific antibody that targets CD274 (PD-L1) and CTLA-4, potentially resulting in enhanced anti-tumor immune response (PMID: 36872527). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05021120 | Phase I | AK127 + Cadonilimab | A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK127 in Combination With AK104 in Advanced and Metastatic Solid Tumours | Recruiting | AUS | 0 |